|
|
|
||
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (30.09.2022)
|
|
||
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (30.09.2022)
The aim of the subject will be to give students basic knowledge of management of neoplasias and also non malignant diaseases of blood. Students will be introduced to epidemiology, clinical signs, staging and basdics of treatment of soild tumors as well as non-malignant hematology disorders. The course will also enable to gain practical skills in communication with an oncology patient. |
|
||
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (30.09.2022)
Haematology part: Hoffbrand V.A., Moss P.A.H: Hoffbrand´s Essential Haematology, 7. edition, Wiley Blackwell, 2015
|
|
||
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (25.09.2020)
Lectures, seminars, practice at the respective department |
|
||
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (22.04.2020)
For the school year 2019/20120 apply following rules for getting credits and passing exams:
Credits will be given to students who participated in at least 60% of semminars and practical lessons and succeeded in the written test containing 15 questions. Credit will be given during last week of the practical training, Final exam will follow, it will be oral with 3 questions to be answered (1 haematology or haematooncology, 1 oncology, 1 priciples of (hemato)oncology care including special pharmacology). To by eligible for final oral exam the student must have passed the exam from General Foundations of Pathology and Pathophysiology (CVSE3P0011). Terms for final exams will be posted in time in SIS (EXAM DATES)
Topics/questions HEMONK for oral exam 3. year, general medicine
Topics & Questions – Oncology School year 2019/2020
Questions – Hematology for school year 2018/2019 1. Laboratory examination in haematology 2. Morfological classification of anaemia 3. Iron defficiency anaemia 4. Pernicious anaemia 5. AIHA 6. TTP/HUS 7. Thalassemia and sicle cell disease 8. PNH 9. Hereditary spherocytosis and G-6-P-D deficiency 10. Aplastic anaemia 11. Neutrophilia and its causes 12. Neutropenia and its causes 13. Eosinophilia and its causes 14. Lymphocytosis and its causes 15. Thrombocytopenia: causes and 16. ITP 17. Thrombocytosis and its causes 18. Thrombocytopathy 19. Acute myeloid leukaemia (AML) 20. Acute lymphoblastic leukaemia (ALL) 21. Chronic myelogenous leukaemia (CML) 22. Primary (idiopathic) myelofibrosis (PMF) 23. Polycythaemia vera 24. Essential thrombocytaemia (ET) 25. Chronic lymphocytic leukaemia (CLL) 26. Lymphoma classification and staging 27. Hodgkin's lymphoma (HL) 28. Diffuse large B cell lymphoma (DLBCL) 29. Mantle cell lymphoma (MCL) 30. Follicular lymphoma (FL) 31. Burkitt's lymphoma (BL) 32. Marginal zone lymphoma (MZL) 33. Waldenström's macroglobulinaemia 34. T- cell lymphoma 35. MGUS 36. Multiple myeloma 37. Alkylating agents, antimetabolites and topoisomerase inhibitors in the treatment of neoplastic diseases F 38. Anthracyclins, platinating agents, nukleoside analogs in the treatment of neoplastic diseases F 39. Corticosteroids in the treatment of neoplastic diseases F 40. Targetted („biological“) therapy in hematooncology F 41. Supportive care in hematooncology, treatment of pain F 42. Hemophilia 43. Von Willebrand's disease 44. Anticoagulation treatment. Heparin, Warfarin and new oral anticoagulants F 45. Antiaggregation treatment F 46. DIC 47. Thrombosis a thrombophilia 48. Antiphospholipid syndrome, lupus anticoagulans 49. Blood products, indication for transfusion and complications 50. Blood derivatives, indication to administration, complications
|
|
||
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (25.09.2020)
Syllabus HEMONK 2019/2020
|